Clinical outcome
T2DM
BLOOD, HYPERTENSION
In this post-hoc analysis, the outcome variables were inflammatory biomarkers (leukocytes, interleukin-6, hsCRP, neutrophil granulocytes, neutrophil-to-lymphocyte ratio) defined as mean changes from baseline to 26 weeks. Blood samples were collected and centrally analysed from all study patients at baseline (randomisation), after 6 weeks (visit 2), and after 26 weeks (visit 4).Explanatory variables in this post-hoc analysis include age, sex, treatment groups (Empagliflozin vs. placebo), hypertension, T2DM, smoking behaviour, NTproBNP, systolic function (LVEF), and diastolic function (E/E’), smoking status, body mass index (BMI), estimated glomerular filtration rate (eGFR), and lipid status. IL-6 and hsCRP were measured on the automated platform Cobas 8000, c-modul 702. The applied methods were the Elecsys IL-6 sandwichassay and Tina-quant C-Reactive Protein IV particle enhanced immunoturbidimetric assay technology (Roche Diagnostics, Mannheim, Germany).